The COVID pandemic shined a light on two areas of historical weakness in the clinical research industry – a slowness to adopt technology and a lack of proactive planning to ensure clinical trial subject diversity – but also exposed the industry’s potential for tremendous achievements in each of these areas. In this webinar, the first to highlight the 2020 Avoca Industry Research involving representatives from over 150 companies, you will learn about how the events of 2020 accelerated operational and study design innovations within clinical development, how respondents perceived various aspects of clinical trial quality, patient diversity, and efficiency to have been impacted, what drivers and impediments arose, and whether respondents anticipated a “snap back” to pre-innovation approaches and perceptions, or an acceleration of innovation, post-Covid-19. We will also explore respondents’ perceptions of the performance of their own companies, and the industry as a whole, with respect to diversity in clinical trial participation, and with respect to true preparedness for deployment of clinical research innovations. Finally, we will discuss how experiences and perceptions vary across companies within the industry, with a focus on what this tells us about leading practices for success in these areas.
Through this discussion, participants will gain insights regarding:
• how the events of 2020 affected use of operational and study design innovations in clinical development
• whether processes “kept up” and how quality, efficiency, and diversity were impacted
• whether a return to pre-2020 status, or an acceleration of innovation, is anticipated post-Covid-19
• critical success factors and leading practices for successful adoption of clinical trial innovations.
This event is part of the 2021 Jon Lee Webinar Series